Carmell Corporation (CTCX)
| Previous close | 2.0500 |
| Open | 2.0500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.8200 - 2.2003 |
| 52-week range | 1.7000 - 13.3100 |
| Volume | |
| Avg. volume | 6,664 |
| Market cap | 45.607M |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCarmell Announces Successful Closing of $3.0 Million Private Placement
PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors (the “Private Placement”). The Company received gross proceeds from the Private Placement of $3 million, excluding offering expenses. The Company issued and sold an aggregate amount of 1,331,452 shares of
- GlobeNewswire
Carmell Announces $3.0 Million Private Placement
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting of
- GlobeNewswire
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable. “The sale
